obesity drug news today glp-1 october 27 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford Market pressure seen as fueling

Let's talk about that

(2025, Nature Metabolism ) reported daLUXendin and daLUXendin+, non-lipidated and lipidated dual GLP-1/GIP receptor agonist fluorescent probes with nanomolar affinity at both hGLP1R and hGIPR

Products are intended strictly for laboratory research and are not for human or veterinary use

30-Day Money-Back Guarantee A Revolution in Nutrition Technology Why Leading Brands Choose Nutrastrips Pioneering Expertise Our team has perfected oral dissolving strip technology that others cant replicate, helping you lead in product innovation

Supports Reduced Inflammation: Helps soothe inflammatory pathways to improve comfort, mobility, and long-term joint wellness

Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two multicenter, double-blind, placebo-controlled Phase 3 trials with safety-extension data